BioTelemetry, Inc. Appoints Colin Hill to Its Board of Directors
May 06 2016 - 4:05PM
BioTelemetry, Inc. (NASDAQ:BEAT) the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care, announced today
the appointment of Colin Hill to its Board of Directors.
Joseph Capper, President and Chief Executive Officer of
BioTelemetry, Inc., commented, “We are pleased to announce the
addition of Colin Hill to the BioTelemetry Board of Directors.
Mr. Hill’s impressive leadership experience in machine
learning in the precision medicine and managed care industries will
be instrumental in helping to shape the Company’s strategic
direction, especially in the era of big data and personalized
medicine. We are extremely fortunate to be adding such a
highly-skilled professional like Colin to an already impressive
team of accomplished independent Directors. I look forward to
working with him as we develop and grow the Company.”
Mr. Hill co-founded GNS Healthcare in 2000 and has served as
Chairman and Chief Executive Officer since its inception. He
serves as Chairman of Via Science, a leading machine learning and
simulation company focused on the Internet of Things, business
intelligence, and security. He was appointed in 2015 by
Massachusetts Governor Charlie Baker to the Board of Directors of
the Center for Health Information and Analysis.
Mr. Hill is also a founding Board member of Transforming
Medicine: The Elizabeth Kauffmann Institute, a non-profit
foundation dedicated to the advancement of personalized
medicine. Mr. Hill also was a founding member of the Board of
Directors of AesRx, a biopharmaceutical company dedicated to the
development of new treatments for sickle cell disease, which was
acquired by Baxter International Inc. in 2014. In 2004, Mr.
Hill was named to MIT Technology Review’s TR100 list of top 100
innovators in the world under age 35.
About BioTelemetryBioTelemetry, Inc., formerly
known as CardioNet, Inc., is the leading wireless medical
technology company focused on the delivery of health information to
improve quality of life and reduce cost of care. The Company
currently provides cardiac monitoring services, original equipment
manufacturing with a primary focus on cardiac monitoring devices
and centralized cardiac core laboratory services. More
information can be found at www.gobio.com.
Cautionary Statement Regarding Forward-Looking
Statements This document includes certain forward-looking
statements within the meaning of the “Safe Harbor” provisions of
the Private Securities Litigation Reform Act of 1995. These
statements may be identified by words such as “expect,”
“anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises”
and other words and terms of similar meaning. Such
forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including important
factors that could delay, divert, or change any of these
expectations, and could cause actual outcomes and results to differ
materially from current expectations. These factors include,
among other things, our ability to successfully integrate
acquisitions into our business and the effect such acquisitions
will have on our results of operation, effectiveness of our cost
savings initiatives, relationships with our government and
commercial payors, changes to insurance coverage and reimbursement
levels for our products, the success of our sales and marketing
initiatives, our ability to attract and retain talented executive
management and sales personnel, our ability to identify acquisition
candidates, acquire them on attractive terms and integrate their
operations into our business, the commercialization of new
products, market factors, internal research and development
initiatives, partnered research and development initiatives,
competitive product development, changes in governmental
regulations and legislation, the continued consolidation of payors,
acceptance of our new products and services, patent protection,
adverse regulatory action, and litigation success. For
further details and a discussion of these and other risks and
uncertainties, please see our public filings with the Securities
and Exchange Commission, including our latest periodic reports on
Form 10-K and 10-Q. We undertake no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise.
Contact: BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
InvestorRelations@biotelinc.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024